MAY 21, 2018 02:58 PM PDT
Common Antibacterial Chemical may Help Fight Lung Infections
WRITTEN BY: Carmen Leitch
2 7 327

Triclosan is a chemical that was added to many different household and personal products. New research has found that it may help fight deadly illness, including cystic fibrosis (CF), when it is used with another drug that has already been approved by the Food & Drug Administration, tobramycin. CF is a genetic disease impacting about one in every 2,500 to 3,500 people; it causes a buildup of thick mucus in the lungs. That mucus is a magnet for pathogenic bacteria, which thrive in a protective biofilm. When triclosan is combined with tobramycin, it kills cells that protect the CF bacteria.

This is a comparison of the cystic fibrosis bacteria, which becomes a green color under fluorescent light, shown before and after treatment. Far right column -- untreated bacteria. Second column -- bacteria treated with tobramycin alone showing some of the bacteria still remaining. Third column -- bacteria treated with triclosan alone showing the majority of the bacteria still remaining. Far left column -- bacteria treated with tobramycin and triclosan showing the effectiveness of the combination treatment. / Credit: Michigan State University

"The problem that we're really tackling is finding ways to kill these biofilms," said Chris Waters, a microbiology professor. Waters is the lead author of the study reporting these findings in the journal Antimicrobial Agents and Chemotherapy.

Many infections that can be chronic and painful are related to biofilms, said Waters; gingivitis and ear infections are two examples. However, those biofilm-related illnesses can be far more serious too. Aside from the infections seen in CF patients, inflammation of the heart or endocarditis can occur, as can infections in biomedical implants like pacemakers or artificial joints.
 
Waters and colleagues conducted a screen to find compounds that could effectively kill these biofilms. Triclosan emerged as a standout.

"It's well known that triclosan, when used by itself, isn't effective at killing Pseudomonas aeruginosa," said Alessandra Hunt, a post-doctoral associate of microbiology and molecular genetics. "But when I saw it listed as a possible compound to use with tobramycin, I was intrigued. We found triclosan was the one that worked every time."

Triclosan was used for many years until concerns emerged that it was being overused. Because it is so good at treating gingivitis, it is still used in toothpaste. It is also still found in hand sanitizer. It was eliminated from most other products.

Biofilms in CF patients are discussed in the video.

"Limiting its use is the right thing to do," said Michael Maiden, a graduate student in medicine. "The key is to avoid creating resistance to a substance so when it's found in numerous products, the chances of that happening increase."

Tobramycin is the most commonly prescribed CF treatment, but it can’t clear the lungs of infection completely, said Waters. The drug can cause hearing loss and it poses a danger to the kidneys. Even though patients inhale the therapy, they remain chronically infected and eventually have to get a lung transplant, if they can.
 
"Most transplants aren't a viable option though for these patients and those who do have a transplant see a 50 percent failure rate within five years," Waters added. "The other issue is that tobramycin can be toxic itself."

"Our triclosan finding gives doctors another potential option and allows them to use significantly less of the tobramycin in treatment, potentially reducing its use by 100 times," Hunt said.

Michigan State University microbiology professor Chris Waters (pictured left), with research associates Micheal Maiden and Alessandra Hunt, have found that a common antibacterial substance found in toothpaste may combat life-threatening diseases such as cystic fibrosis when combined with the already FDA-approved antibiotic tobramycin. /Credit: Derrick Turner

Brushing your teeth with triclosan won’t be enough, Maiden said. But the team wants to test their combination on a mouse model. They are hopeful it will lead to human trials quickly, because both drugs have already been approved.

"We're working to get this potential therapy approved so we can provide a new treatment option for CF patients, as well as treat other biofilm infections that are now untreatable. We think this can save lives."


Sources: AAAS/Eurekalert! Via Michigan State University, Antimicrobial Agents and Chemotherapy

About the Author
  • Experienced research scientist and technical expert...
You May Also Like
MAR 08, 2018
Microbiology
MAR 08, 2018
Photosynthesis Began far Earlier Than Thought
While unclear, it has been thought that photosynthetic organisms evolved around 2 billion years ago. New research has suggested it was actually far earlier.
MAR 28, 2018
Microbiology
MAR 28, 2018
Gut Bacteria may be at the Root of Autoimmune Disorders
Our gastrointestinal system has a close relationship with our health; increasing evidence has shown.
APR 02, 2018
Immunology
APR 02, 2018
How does Johne's disease evade the immune system?
An infectious disease that afflicts cattle all over the world is particularly devastating because it can inhibit the animals’ immune systems. In a ne
MAY 16, 2018
Cell & Molecular Biology
MAY 16, 2018
HIV Caught on Camera Infecting Cells
Scientists have known for a long time that HIV can spread through sexual contact, but the details of the process were not well understood.
MAY 22, 2018
Cancer
MAY 22, 2018
Breakthrough Analysis Outlines Conceivable Cause of Childhood ALL
A team from the Institute of Cancer Research has published a comprehensive literature review and outlined a breakthrough in the causative theory of childhood ALL development.
MAY 31, 2018
Microbiology
MAY 31, 2018
Ulcer-causing Microbe Found to Disrupt Mitochondria
Knowing how H. pylori establishes an infection will help develop better treatments for the pathogen.
Loading Comments...